Page last updated: 2024-10-26

dipyridamole and Paroxysmal Reciprocal Tachycardia

dipyridamole has been researched along with Paroxysmal Reciprocal Tachycardia in 2 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Thormann, J1
Schlepper, M1
Neuss, H1
Lindquist, JR1
George, RP1

Other Studies

2 other studies available for dipyridamole and Paroxysmal Reciprocal Tachycardia

ArticleYear
Coronary hemodynamics in simulated paroxysms of ventricular tachycardia: role of myocardial impairment and of extravascular resistance.
    Cardiology, 1982, Volume: 69, Issue:6

    Topics: Aorta; Aortic Valve Insufficiency; Blood Pressure; Coronary Circulation; Coronary Disease; Dipyridam

1982
Thrombotic thrombocytopenic purpura: onset during dipyridamole therapy.
    JAMA, 1981, Dec-04, Volume: 246, Issue:22

    Topics: Blood Platelets; Dipyridamole; Female; Humans; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Ta

1981